Department of Radiation Oncology, Oncology Center, Universitair Ziekenhuis Brussel (UZB), Brussels, Belgium.
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1352-9. doi: 10.1016/j.ijrobp.2009.06.075. Epub 2010 Jan 7.
To prospectively assess the feasibility, toxicity, and local control of a class solution protocol of moderately hypofractionated tomotherapy in Stage III, inoperable, locally advanced non-small-cell lung cancer patients.
Eligible patients were treated according to a uniform class solution (70.5 Gy in 30 fractions) with fixed constraints and priorities using helical tomotherapy. Toxicity monitoring was performed using the Radiation Therapy Oncology Group criteria and the National Cancer Institute Common Terminology Criteria and Adverse Events (CTCAE) version 3.0. Pulmonary function tests were performed at the start and repeated at 3 months after treatment.
Our class solution resulted in a deliverable plan in all 40 consecutive patients. Acute Grade 3 lung toxicity was seen in 10% of patients. Two patients died during acute follow-up with pulmonary toxicity. Correlations were found between changes in pulmonary function test results and mean lung dose or the lung volume receiving 20 Gy (V(20)). The correlation was strongest for lung diffusion capacity for carbon monoxide. A V(20) of >27% and >32% were predictive for Grades 2 and 3 acute lung toxicity respectively (p < 0.05). Late Grade 3 toxicity was exclusively pulmonary, with an incidence of 16%. Overall Grade 3 lung toxicity correlated with a mean lung dose of >18 Gy and a median lung dose of >5 Gy (p < 0.05). Median survival was 17 months, and the 1-year and 2-year local progression-free survivals were 66% and 50%, respectively.
The current class solution using moderately hypofractionated helical tomotherapy in patients with locally advanced non-small-cell lung cancer is feasible. Toxicity was acceptable and in line with other reports on intensity-modulated radiotherapy. The local progression-free survival was encouraging considering the unselected population.
前瞻性评估适形调强放疗中采用中等分割方案治疗不可手术局部晚期 III 期非小细胞肺癌患者的可行性、毒性和局部控制。
根据统一的类解决方案(30 次分割,每次 70.5Gy),使用螺旋断层放疗为符合条件的患者进行治疗,方案具有固定的约束和优先级。使用放射治疗肿瘤学组标准和国家癌症研究所通用术语标准和不良事件(CTCAE)第 3.0 版进行毒性监测。在治疗开始时和治疗后 3 个月重复进行肺功能测试。
我们的类解决方案在 40 例连续患者中都得到了可交付的计划。10%的患者出现急性 3 级肺毒性。2 例患者在急性随访期间因肺毒性死亡。发现肺功能测试结果的变化与平均肺剂量或接受 20Gy(V20)的肺体积之间存在相关性。肺一氧化碳扩散能力的相关性最强。V20 分别大于 27%和 32%可预测分别为 2 级和 3 级急性肺毒性(p<0.05)。晚期 3 级毒性仅为肺部,发生率为 16%。总 3 级肺毒性与平均肺剂量>18Gy 和中位数肺剂量>5Gy 相关(p<0.05)。中位生存期为 17 个月,1 年和 2 年局部无进展生存率分别为 66%和 50%。
使用适形调强放疗中等分割方案治疗局部晚期非小细胞肺癌的当前类解决方案是可行的。毒性是可以接受的,与其他调强放疗报告一致。考虑到未选择的人群,局部无进展生存率令人鼓舞。